Literature DB >> 6380442

Rifampin drug interactions.

A M Baciewicz, T H Self.   

Abstract

Rifampin, an antituberculosis agent, is usually administered for nine to 12 months with other antituberculosis drugs or drugs from other classes. A potential for drug interactions often exists because this drug is a potent inducer of drug metabolism. Rifampin causes a proliferation of the smooth endoplasmic reticulum and an increase in the cytochrome P-450 content in the liver. Rifampin's enzyme-induction effect is selective; therefore, it is not always clear which agents will be affected. Studies and case reports have demonstrated that rifampin accelerates the metabolism of several drugs, including oral anticoagulants, oral contraceptives, glucocorticoids, digitoxin, quinidine, methadone, hypoglycemics, and barbiturates. Rifampin interacts with other agents, but further study is needed to demonstrate the clinical importance of these interactions. In addition to inducing drug-metabolizing enzymes, rifampin may cause alterations in absorption and hepatic uptake. Future investigations will probably identify new rifampin drug interactions.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6380442     DOI: 10.1001/archinte.144.8.1667

Source DB:  PubMed          Journal:  Arch Intern Med        ISSN: 0003-9926


  27 in total

1.  Prevalence of Hepatotoxicity From Antituberculosis Therapy: A Five-Year Experience From South India.

Authors:  Arunava Saha; Margaret Shanthi F X; Blessed Winston A; Saibal Das; Aniket Kumar; Joy S Michael; T Balamugesh
Journal:  J Prim Care Community Health       Date:  2016-04-07

2.  Possible implications of doxycycline-rifampin interaction for treatment of brucellosis.

Authors:  J D Colmenero; L C Fernández-Gallardo; J A Agúndez; J Sedeño; J Benítez; E Valverde
Journal:  Antimicrob Agents Chemother       Date:  1994-12       Impact factor: 5.191

3.  Multiple-dose pharmacokinetics of concurrent oral ciprofloxacin and rifampin therapy in elderly patients.

Authors:  M H Chandler; S M Toler; R P Rapp; R R Muder; J A Korvick
Journal:  Antimicrob Agents Chemother       Date:  1990-03       Impact factor: 5.191

Review 4.  Pharmacokinetic interactions with digoxin.

Authors:  S M Rodin; B F Johnson
Journal:  Clin Pharmacokinet       Date:  1988-10       Impact factor: 6.447

Review 5.  Clinically significant interactions with drugs used in the treatment of tuberculosis.

Authors:  W W Yew
Journal:  Drug Saf       Date:  2002       Impact factor: 5.606

6.  Steady-state serum pharmacokinetics of novobiocin and rifampin alone and in combination.

Authors:  G L Drusano; R J Townsend; T J Walsh; A Forrest; E J Antal; H C Standiford
Journal:  Antimicrob Agents Chemother       Date:  1986-07       Impact factor: 5.191

7.  The influence of antituberculosis drugs on the plasma level of verapamil.

Authors:  J Mooy; R Böhm; M van Baak; J van Kemenade; A vd Vet; K H Rahn
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

8.  Drug interaction between lorcainide and rifampicin.

Authors:  V F Mauro; P Somani; P N Temesy-Armos
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

9.  Enhanced elimination of ciprofloxacin after multiple-dose administration of rifampin to rabbits.

Authors:  S L Barriere; G W Kaatz; S M Seo
Journal:  Antimicrob Agents Chemother       Date:  1989-04       Impact factor: 5.191

10.  Age-dependent stereoselective increase in the oral clearance of hexobarbitone isomers caused by rifampicin.

Authors:  D A Smith; M H Chandler; S I Shedlofsky; P J Wedlund; R A Blouin
Journal:  Br J Clin Pharmacol       Date:  1991-12       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.